BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

BNTX upcoming catalysts

BioNTech SE: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 8 readout(s) and 0 FDA event(s). Subscribe to BNTX (.ics).

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2BioNTech SE BNTXNCT04486378 A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage IColorectal Cancer Stage II; Colorectal Cancer Stage IIIactive not recruiting327
2026-09-22P3BioNTech SE BNTXNCT07300839 A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of AgeCOVID-19; SARS-COV-2 Infectioncompleted5240
2026-07-24P3BioNTech SE BNTXNCT07222384 A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe CCOVID-19; SARS-COV-2 Infectioncompleted344
2026-07-10P3BioNTech SE BNTXNCT05543616 A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy ChildrenSARS-CoV-2 Virus; Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19completed4338
2026-05-01P3BioNTech SE BNTXNCT07069309 A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher COVID-19; SARS-COV-2 Infectioncompleted774
2026-03-12P1/P2BioNTech SE BNTXNCT05547464 Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated VolunteersTuberculosisactive not recruiting497
2025-12-22P1/P2BioNTech SE BNTXNCT05262530 Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid TumorsSolid Tumorterminated73
2025-12-17P1/P2BioNTech SE BNTXNCT06821061 A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy PeopleInfluenza; COVID-19 (Coronavirus Disease 2019)completed2650

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.